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Abstract  
Psyllium has a mucilaginous property that makes it a good candidate to be utilized as an 
excipient in the preparation of controlled release systems. Various formulations were prepared 
using theophylline as a model drug and investigated with view to achieve an ideal slow drug 
release profile. The addition of HPMC to psyllium significantly reduced burst release however 
the percentage of drug release within a 12 h period was too slow and thereby inadequate. This 
was overcome by the addition of lactose as hydrophilic filler which enabled a slow release with 
roughly 80% drug release in 12 h. The inclusion of HPMC within psyllium formulations changed 
the drug release kinetics from Fickian diffusion to anomalous transport. Granulated formulations 
demonstrated slower drug release than ungranulated or physical mixture and caused a change in 
dissolution kinetics from Fickian diffusion to anomalous transport. Milled granules showed more 
efficient controlled drug release with no burst release. Milling of the granules also changed the 
drug release kinetics to anomalous transport. Although, psyllium was proved to be a promising 
polymer to control the drug release, a combination of psyllium-HPMC and formulation processes 
should be considered in an attempt to achieve a zero-order release. 
  
Keywords: Psyllium, Theophylline, HPMC K4M, sustained release, dissolution, hydration, 
release mechanism and granulation. 
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Introduction 
Several oral sustained release formulations have been developed including film coated 
preparations, osmotic devices, floating systems, bioadhesive systems and matrix systems. These 
oral preparations can be subdivided into two groups: single (manufactured by coating tablets 
with release controlling films or soluble polymers) and multiunit (consist of particles or granules 
of different release profiles that could also be coated with water soluble polymers) preparations. 
Such formulations have several advantages including being useful for once daily dosing (or a 
less frequent dosing regimen), beneficial for drugs that can cause local irritations, reduce the 
incidence of dose related side effects, increase in patient compliance and prolonging the effect of 
the drug by maintaining a steady concentration in the bloodstream. Polymeric materials are 
widely used for controlling the release of drugs. Matrix tablets are polymer based delivery 
systems which enable a slow controlled release of drugs into the body. The swelling of the 
polymeric networks depends on the composition of the polymer and the pH of the surrounding 
medium. [1, 2] Drugs that are covalently bound to polymers or dispersed within the polymer 
matrix are released via diffusion and erosion mechanisms. [3] Researchers have demonstrated that 
the gel layer formed around hydrophilic matrices, upon its contact with gastro-intestinal (GI) 
fluids, is eroded allowing drug release. This erosion is the dominant release mechanism for 
poorly soluble drugs. The other mechanistic approach is that the soluble portion of drug is 
released through the process of diffusion through the gel layer. [4-7] An increase in the polymer 
hydrogel concentration increases the viscosity of the gel layer around the tablets, thereby limiting 
the penetration and release of active ingredient which results in a slower drug release. However, 
formulations with low levels of polymer concentrations could cause an inconstant release and 
initial burst of the drug. [8] 
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Hydroxypropyl methyl cellulose (HPMC) is a synthetic derivative of cellulose and a widely used 
polymer in the production of sustained release matrix tablets due to its rapid hydration, good 
compression, gelling characteristics and very low toxicity. [9] There has been a link established 
between the retarding effects of HPMC to the gelatinous layer formed when the polymer is 
hydrated by water.[10] 
Psyllium could be an effective and cheap therapy for chronic diarrhoea [11], promoting healthy 
bowel function[12-15] as a bulking agent or laxative[16]. It also acts as a substrate for microbial 
growth that increases stool mass[17]. Psyllium decreases post-prandial glucose concentrations in 
men with type II diabetes [18-21]. Recently, psyllium was used for the controlled delivery of 
peptides such as insulin[22]. It has been shown that psyllium could reduce the concentration of 
low-density lipoprotein (LDL) and cholesterol in the plasma,[23]  and can be used in the treatment 
of  irritable bowel syndrome (IBS),[24-27] maintaining remission in ulcerative colitis,[28,29] and 
inhibiting carcinogenic processes.[30,31] 
Psyllium not only has pharmacological importance but it also can be used to develop drug 
delivery devices such as sustained release matrix tablets and hydrogels. Psyllium has a 
characteristic of forming a viscous gel almost immediately when in contact with water and so the 
drug release rate is controlled quicker.[32] The hydrogel matrix formed by psyllium resists 
hydrolysis; therefore psyllium can resist colonic bacterial degradation. Therefore, the double 
potential of the psyllium hydrogel can be used to prepare novel drug delivery systems.[33] 
Psyllium is also relatively safe with low toxicity [34] cost effective, [35-38] and has global consumer 
acceptance having been used for hundreds of years in traditional medicines and products and it 
has been approved by the FDA.[39] Several researchers have modified psyllium husk powder to 
improve its application in drug delivery systems. Gohel et al. [40] modified psyllium husk powder 
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with tartaric and succinic acid to develop a suitable sustained release tablet for diltiazem HCl via 
direct compression. The treated psyllium husk powder showed better gelling and swelling 
characteristics.  Kaith and Kumar[41] modified psyllium with acrylic acids using potassium 
persulphate and hexa- methylene tetramine (KPS-HMTA) to optimize the polymer gel. They 
found the gel produced to be pH and temperature sensitive and selective towards water 
absorption from oil-water emulsions. Singh et al. [33] modified psyllium hydrogels by using 
acrylic acid and radiation. They showed the psyllium hydrogels developed to have the capability 
to be used as double potential drug delivery devices in the colon and to provide drug release in a 
controlled and sustained manner. Siahi-Shadbad et al. [42] evaluated the release behaviour of 
propranolol HCl from psyllium matrices in the presence of HPMC K4M, sodium alginate, 
sodium carboxy methylcellulose (NaCMC) in different concentrations on the drug release from 
psyllium matrices. They found that binary mixtures of psyllium and HPMC, psyllium and 
sodium alginate and NaCMC and psyllium in various ratios caused a significant decrease in the 
release rate of propranolol HCl. As the type of filler can change the drug release profile, in the 
present study the authors focused on the effect of the type of filler on the drug release from tablet 
matrices containing psyllium. The present research work further investigated the effect of 
granulation and milling on the performance of psyllium in controlling the drug release in tablet 
matrices. 
Theophylline (1,3-dimethyl xanthine) is a potent methylxanthine bronchodilator widely used in 
the treatment of asthma, chronic obstructive airways disease (COAD) and bronchospasm in 
adults. For drugs such as theophylline, it is beneficial to have a steady plasma concentration over 
night to reduce symptoms experienced early in the morning, hence preparation a sustained 
release formulation for theophylline is highly beneficial. [43-46] 
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In the present study, theophylline was chosen as the model drug for evaluating the polymer 
psyllium for sustained release. Lactose and EmcompressR (dicalcium phosphate dehydrate) were 
used as two examples of hydrophilic and hydrophobic fillers respectively. The key aim of this 
project is to show promising release behaviour of drug in the presence of psyllium under 
different processing conditions.  
Materials and methods 
Materials 
Theophylline anhydrous, potassium phosphate monobasic and calcium phosphate dibasic 
dihydrate (Emcompress) were purchased from Acros Organics, USA. Sodium hydroxide and 
Magnesium stearate were obtained from Fisher Scientific, UK. HPMC K4M Premium and 
psyllium (>99% purity) were supplied by Colorcon, UK and Shiv Psyllium Industry, India 
respectively. Micronized lactose was generously supplied by DMV International, Netherland. 
Phosphate buffer (pH 6.8) was prepared according to the USP method. 
Psyllium husk milling 
The psyllium husk was milled for 15 min using a Ball mill (Pulverisette, RS232, Fritsch) at 400 
rpm to reduce the particle size. The Ball mill rotates around a horizontal axis and thereby the 
stainless steel balls cause an internal cascading effect which reduces the husk into a fine powder. 
Preparation of powder mixtures 
The preparation of physical mixture formulations was studied as listed in Table 1. The weight 
and composition of the powder mixture ratios for the granulation process are listed in Table 2. 
The powders for each formulation were mixed in a Turbula® (Type T2 C, Switzerland) blender 
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for 10 min, after which the equivalent weight of the 1% Magnesium stearate as listed in Tables 1 
and 2, was added as a lubricant. The contents were then mixed for a further 5 min. 
Wet granulation 
Following theophylline-polymers mixing, 7 mL of distilled water was added using a pipette (10 
ml borosilicate pipette was used). Using a pestle and mortar, this was ground into a paste. The 
paste was then sieved using a 1 mm sieve to produce granules which were then transferred into 
the drying oven set at 65 ºC for 1 h. The second method used for granulation was similar to the 
first method; however, the active drug theophylline was not added to the initial mixture. The 
polymers were first granulated and dried in the oven, then theophylline was added, and the 
contents were mixed for 10 min in the Turbula mixer. Only 4 mL of distilled water was used for 
the granulation of the polymers with Emcompress® and lactose. In the final method, the 
granulation steps stated above were repeated; however, the granules produced were milled for 10 
min in the ball mill. The milling and granulation processes bears relevance in industry, as such, 
the authors believe the employed methodology has application in industry on a large scale.  
 
Tablet Preparation 
Tablets, 10 mm round concave, with target weights as detailed in (Tables 1 and 2) were weighed 
and were compressed using a single punch tableting machine (Model MTCM-1, Globe Pharma, 
US) at 2000 psi (7.65 kN). The die wall was lubricated each time after tablet compression with a 
1% w/v suspension of magnesium stearate in acetone to enable easy ejection of the tablets from 
the die. The mean tablet weight was 405.2 ±1.0 mg.  
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Dissolution Testing 
The in-vitro dissolution tests were performed on the USP dissolution apparatus 1 (basket 
method) (Varian Auto Sampler, VK 7010), using 900 mL phosphate buffer (pH 6.8) with a 
rotation speed of 100 rpm. The temperature of the dissolution medium was maintained at 
37.2±0.1 ºC. Agitation was stopped after a 12 h period. Theophylline released was measured at 
271 nm using a UV/Visible spectrophotometer (Varian, Cary 50). Each dissolution data point 
represents the mean of minimum three dissolution runs.  
 
Release Kinetics 
The kinetics of drug release was analyzed using Peppas equation (the equation below) [47] as 
detailed previously. [48] 
Q=ktn 
Where Q is the fraction of drug release in time t, k is the rate constant incorporating 
characteristics of the macromolecular network system and the drug, and n is the diffusional 
exponent (for more details refer to discussion section). 
 
Differential Scanning Calorimetry (DSC) 
This was performed as detailed previously.[49] In this study the flat faced 4 mm mini tablets with 
a target weight of 20 mg were compacted at 2000 psi (7.65 kN). Due to the poor compactability 
of psyllium’s mini tablets, a mixture of 50 % psyllium and 50 % HPMC was utilised. The discs 
were hydrated for 10 minutes using 25 mg of phosphate buffer (pH 6.8) in a standard aluminium 
pan sealed with a lid. The aluminium pans were firstly cooled down from ambient temperature 
(25oC) to -30oC at 55oC/min in order to freeze any unbound (free) water; then kept at -30oC for 5 
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minutes for equilibration to occur and heated up again from -30oC up to 50oC at 10oC/min under 
nitrogen gas to determine the amount of free and bound water using endotherm scanning of the 
melted free water. The reference standard using phosphate buffer (pH 6.8) was prepared using 25 
mg of phosphate buffer (pH 6.8) in standard aluminium pan sealed with a lid and allowing it to 
go through the same process as the hydrated disks. The integration of the endotherm represented 
100% free water. From this deduction, bound and free water were determined.  All these 
experiments were performed in triplicate. 
Scanning Electron Microscopy (SEM) 
The psyllium husk and the ground psyllium were coated with gold using an ion sputter coater. 
The coated samples’ morphologies were then viewed using a SEM (Stereoscan 360 – Edward 
sputter coater-gold coater, S150B, Cambridge instruments UK LTD) operating at 10 kV. 
Micrographs were taken at different magnifications. 
 
 Results and discussion 
Dissolution 
Release profiles of theophylline from physical mixtures composed of psyllium:theophylline or 
psyllium:HPMC:theophylline are depicted in Figures 1-a and 1-b respectively. There was a 
reduction in theophylline release with an increase in psyllium concentration (Figure 1-a). The 
increase in psyllium content also was able to supress the initial burst release observed (Figure 1-
a). For example, the burst release of theophylline decreased from 58% when the polymer content 
was at 33.3% to 23% drug released when the polymer level increased to 50% (Figure 1-a). 
Interestingly, the inclusion of HPMC to the physical mixture of theophylline and psyllium 
improved the quality of the tablets and drug release profiles with the burst release of the drug 
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being significantly reduced (p<0.05) (Figure 1-b). For example, the incorporation of 12.5 % 
HPMC reduced the burst effect seen for the 50% psyllium from 28% (Figure 1-a, 50% psyllium-
50% drug) to 7% (Figure 1-b) and further additions of HPMC reduced it further to 3% (Figure 1-
b).  
The tablets made of granulated psyllium had a very similar drug release profile to the one where 
psyllium and theophylline were granulated together (Figure 1-c). This suggests that there is a 
change in the polymer and perhaps better uniformity that leads to better dissolution profiles. 
Figure 1-c implies that the effect of the addition of HPMC to the psyllium formulation and using 
granulation techniques at the various ratios also demonstrated a release profile similar to zero-
order (n values for these formulations varied between 0.719-0.790 indicating erosion is the main 
mechanism of drug release); however, there was still only about 40% of drug release within 12 h. 
The granulated samples showed relatively similar release profiles in all the formulations under 
study (e.g. Figure 1-c). By comparing the granulated vs. un-granulated dissolution profiles 
(Figures 1-b, -c), it was clear that the granulated psyllium formulations have a slower drug 
release in comparison with the un-granulated formulations.   
Figures 2-a, -b show the dissolution profiles of theophylline from granulated psyllium or HPMC 
and Emcompress formulation versus the milled granules. The combination of using wet 
granulation followed by milling of the granules exhibited interesting results for all the 
Emcompress and psyllium formulations. Hydrophobic fillers like Emcompress do not dissolve in 
water. Therefore the drug can only diffuse out of the limited gaps within the polymer and the 
majority of the drug release will depend on the disintegration or erosion of the polymeric matrix 
leading to a slower drug release rate as demonstrated in Figures 2-a, -b. This could be due to 
several factors. First, milled granules have increased surface area for hydration, decreased 
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porosity and water penetration and thereby the drug release is controlled in a more efficient 
manner after the polymer swelling. Secondly, the formulations consisting of the granules have 
higher porosity and therefore the drug diffuses out of the matrix much faster.  
Figure 3 shows a graph of 2 formulations with the same ratios, however different excipients, 
namely, psyllium and lactose versus psyllium and Emompress both after granulation and milling. 
Both formulations demonstrated very similar release profiles with more than 70% of drug release 
after 10 h, however the formulation containing Emcompress being slightly slower but not 
significant statistically (p > 0.05) (Figure 3). Such result reinforces the beneficial effects of 
psyllium in forming a variation of robust formulations.  
Figures 4-a, -b show the dissolution profiles of theophylline from granulated psyllium or HPMC 
and lactose formulation versus the milled granules. The presence of a hydrophilic filler such as 
lactose leads to a faster dissolution rate. This is because lactose dissolves in contact with water. 
Once the lactose has dissolved, gaps are left within the polymer which allows the drug to diffuse 
out of the system. The drug release profiles for the milled samples in formulations containing 
psyllium and HPMC (Figure 4-a) exhibit release profiles similar to zero order release. The 12.5% 
and 25% psyllium or HPMC content of formulations that were milled showed a slow release 
pattern with over 70% drug release within 12 h. In the case of milled formulations containing 
either psyllium or HPMC, no remarkable burst release was observed (Figures 4-a, -b). In 
contrary, theophylline formulated with both HPMC and lactose granules showed undesirable 
initial burst release (Figures 4-b) which could be due to the presence of drug particles on the 
surface of the matrix.42 This indicates that the milling had a remarkable influence on the drug 
dissolution profiles from the matrix. Indeed, the hydration of the polymer is believed to be at 
faster rate in the case of milled formulations due to reduced particle size, as proved later. This 
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suppressed the burst release and had the drug profiles exhibiting profiles similar to zero order 
release pattern. 
Figure 5 compares two formulations:  25 psyllium + 25 Lactose: 50 drug and 25 HPMC + 25 
Lactose: 50 drug. Both formulations demonstrated very similar release profiles with an adequate 
amount of drug being released within 12 h; however, the formulation containing psyllium had a 
slightly slower (p<0.05) release rate in comparison to the formulation containing HPMC. 
The release of the drug from a swellable hydrophilic matrix initiates with the penetration of 
water into the matrix. In matrix systems, the drug is homogenously dispersed throughout a rate 
controlling medium. Next, the drug is dissolved and the penetrated water hydrates the polymer 
and causes swelling to form a gel like structure, thereby bringing about a relaxation of the 
polymer chains and consequently the polymer mesh size increases. This enables the drug to 
diffuse through the swollen network of the matrix out to the external environment. Therefore, the 
release of the drug is very closely related to the swelling characteristic of the psyllium hydrogel. 
In erodible systems, the mechanism of drug release occurs by bulk erosion or surface erosion. If 
bulk erosion occurs, the polymer degradation occurs through bulk hydrolysis; however, if surface 
erosion occurs, only the surface of the polymer degrades resulting in a release rate that is 
proportional to the surface area of the delivery system. In this study, theophylline is considered 
to have medium water solubility [50] and psyllium forms gel matrix thus both erosion and 
diffusion could occur. Mathematical models were used to evaluate the kinetics and mechanisms 
of drug release from the tablets. For matrix (cylindrical) tablets, an n value equal to or less than 
0.45 indicates Fickian diffusion (or case-I) mainly controlled by diffusion.  For n ≥ 0.89 (i.e. 0.89 
< n <1.00), a super case-II transport takes place, when dissolution process is controlled mainly 
by erosion and the release rate is independent of time (‘zero-order’ kinetics). Intermediate values 
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(i.e. 0.45 ≤ n ≤ 0.89) represent a non-Fickian or anomalous transport and suggest that erosion 
(polymer matrix relaxation) and drug diffusion both contribute to the overall drug release 
mechanisms. [51] 
The physical mixture of the pysllium and drug as in Figure 1 had Fickian diffusion as its sole 
kinetics of drug release with n values ranging from 0.102–0.233 (Table 3). The n values however 
seemed to increase with increasing psyllium content. The inclusion of HPMC changed the drug 
release kinetics from Fickian diffusion to anomalous transport indicating that a combination of 
erosion and diffusion taking place with n values ranging from 0.482–0.745 (Table 3). 
Granulation also had a remarkable effect on the drug release kinetics. A look at the n values of 
the pysllium and drug physical mixture formulation (n = 0.102) and the pysllium and drug 
granulated formulation (n =0.719) in the ratio of 1:1 suggest that there is a change from Fickian 
diffusion to anomalous transport (Table 3) caused by granulation during formulation preparation. 
Figure 6 shows the appearance of tablets made from 50% theophylline + 50 % psyllium physical 
mixture (ungranulated) and from granulated psyllium-theophylline after 12 h dissolution period. 
The tablets made from granulated powders maintained their integrity after the dissolution 
compared to ungranulated formulations. The nature of the tablet after the dissolution process 
which could be a contributory factor to why there was such a remarkable change in the drug 
release kinetics. All granulated formulations of psyllium, HPMC and drug were dominated by 
anomalous transport whereas all granulated formulation of HPMC or psyllium with lactose or 
Emcompress had Fickian diffusion dominating their kinetics of drug release. Milling after the 
granulation process however changed their drug release kinetics to anomalous transport (Table 
3). 
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Scanning Electron Microscopy 
To investigate the effect of milling on the psyllium husk particles, SEM photographs of the 
milled and un-milled husk was taken at different magnifications as shown in Figure 7. SEM 
image of un-ground psyllium husk showed large particles with irregular-elongated shape (Figure 
7). Such elongated shape could be a possible reason for the poor compactability and 
compressibility observed of the psyllium husk.[42] Following milling, psyllium husk particles 
demonstrated reduced size and irregular-flat shape (Figure 7), both could contribute to the poor 
compressibility of the psyllium powder. Also, this could lead to an increased surface area for 
hydration and gelling for the psyllium. 
 Differential Scanning Calorimetry 
DSC was conducted to investigate the hydration of the polymers (Figure 8). From basic 
observations, the mini tablets containing psyllium swelled immediately and faster than the 
HPMC samples, even before the cap closing of the aluminium crucible. However, it is worth 
noting that psyllium had poor compactibility and the mini tablets crumbled despite the efforts to 
decrease/increase the weight of the mini- tablet and increasing the tablet compaction force. 
Therefore HPMC was added and the effect of psyllium on the hydration of HPMC was observed. 
Each sample was allowed 10 min for the phosphate buffer (pH 6.8) to penetrate the polymer.  
The first exothermic curves indicate the freezing process. The endothermic transitions 
correspond to the melting of the free water in each sample (Figure 8). Melting enthalpy and all 
transition temperatures for all samples are listed in Table 4. The values of the percentage bound 
water shows HPMC improves the hydration of psyllium (Table 4). HPMC granules demonstrated 
a slightly slower rate of hydration compared to psyllium granules which could be due to a 
decrease of the surface area of the particles. In matrix systems, the drug is dispersed as fine solid 
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powder particles within a porous matrix. Initially, the drug particles on the surface of the release 
unit are dissolved and the drug is released rapidly. Table 4 also shows psyllium to bind less to 
water than HPMC, meaning more water being available for the hydration process and for the 
movement of drug particles. This is evident in Figure 1a and b where drug release is quicker for 
psyllium as compared to HPMC only. The diffusion of the active ingredient out of the matrix 
system greatly depends on the water content of the tablet. This could be due to the fact that 
mobility of the polymer chains is dependent on water content. At a higher water concentration, 
polymer chain relaxation occurs leading to volume expansion which in turn moves the diffusion 
boundaries.[47]Aoki and co workers[52] explained that during the initial stages of dissolution, 
water penetrates into the matrix and usually acts as non-freezing (bound) water. In the next stage 
consists of  the water content of the matrix increasing and freezable water being detected at 
levels related to drug release. They also reported that the transport of solutes mainly occurs 
through the free water and that only little transport occurs through bound water.[52] Asare-Addo 
and co workers[49]  also hydrated K chemistry HPMC polymers with theophylline as a model 
drug and found the hydration at the 10 min time point to correlate with drug release from their 
dissolution studies.  
Conclusion  
This study proved that psyllium is a potential polymer which is capable to generate a wide 
variation of robust formulations. Reduced theophylline release with restrained initial burst 
release was proved with increasing psyllium concentration. Improved tablet quality and drug 
release profiles with lower initial burst release were obtained when HPMC was incorporated 
with formulations consisting of theophylline-psyllium physical mixtures. Also, a release profile 
comparable to zero-order was obtained when HPMC was granulated with psyllium. All 
  
16 
 
granulated formulations demonstrated relatively similar release profiles; however, granulated 
formulations generated slower drug release than un-granulated formulations. A change in drug 
release kinetics from Fickian diffusion to anomalous transport was observed when HMPC was 
included with the theophylline formulations. 
Psyllium and lactose or Emcompress formulations could be utilized to achieve an ideal drug 
release profile close to zero order release. Psyllium could also be used in conjunction with 
HPMC to achieve a variety of drug release profiles that could be beneficial for certain drugs. 
Both milling and granulation had a significant effect of drug release. Milling was proved useful 
in obtaining controlled dissolution profiles similar to that of zero-order. This could be due to an 
increase in uniformity; however, it could have also been due to a further reduction in the polymer 
particle size which increases the surface area for hydration and exhibits a slower dissolution rate. 
Milling following granulation process altered drug release kinetics to anomalous transport. 
The use of psyllium in the production of sustained release oral formulations is a very fruitful area 
for research. The wide range of therapeutic and physiological benefits and the economical/cost 
effectiveness that psyllium has makes it a superb candidate for a novel double potential drug 
delivery device.  
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Table 1. Required weight of excipients for preparing physical mixture formulations with 
different ratios 
Drug 
ratio 
Psyllium 
ratio 
HPMC 
ratio 
Theophylline 
(mg) 
Psyllium 
(mg) 
HPMC 
K4M (mg) 
Mg Stearate 
(mg) 
Tablet 
(mg) 
66.6 33.3 … 1000 500 … 15 303 
60.0 40.0 … 1000 666.65 … 16.66 336.66 
55.0 45.0 … 1000 818.18 … 18.18 367.27 
52.5 47.5 … 1000 904.76 … 19.04 384.76 
50.0 50.0 … 1000 1000 … 20 404 
50.0 … 50.0 1000 … 1000 20 404 
50.0 12.5 37.5 1000 250 750 20 404 
50.0 37.5 12.5 1000 750 250 20 404 
50.0 25.0 25.0 1000 500 500 20 404 
 
Table 2. The composition of each formulation for granulated formulations  
Ratio (%) Weight (mg) 
 Psyllium HPMC Lactose EM  Psyllium HPMC-K4M  Lactose EMC Tablet 
 50 … … …  1000 …  … … 404 
 … 50 … …  … 1000  … … 404 
 12.5 37.5 … …  250 750  … … 404 
 25 25 … …  500 500  … … 404 
 37.5 12.5 … …  750 250  … … 404 
 25 … 25 …  500 …  500 … 404 
 37.5 … 12.5 …  750 …  250 … 404 
 12.5  37.5 …  250 …  750 … 404 
 … 25 25 …  … 500  500 … 404 
 … 37.5 12.5 …  … 750  250 … 404 
 … 12.5 37.5 …  … 250  750 … 404 
 25 … … 25  500 …  … 500 404 
 37.5 … … 12.5  750 …  … 250 404 
 12.5 … … 37.5  250 …  … 750 404 
 … 25 … 25  … 500  … 500 404 
 … 12.5 … 12.5  … 750  … 250 404 
 … 37.5 … 37.5  … 250  … 750 404 
a
 the ratio of theopylline was 50% or 1000 mg 
b
 the amount of magnesium stearate was 20 mg   
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Table 3. Kinetics of drug release for different formulations under investigation 
Drug Psyllium HPMC Lactose EM Compress Formulation type* n value 
66.6 33.3 … … … Physical mix 0.102 
60 40 … … … Physical mix 0.146 
55 45 … … … Physical mix 0.216 
52.5 47.5 … … … Physical mix 0.215 
50 50 … … … Physical mix 0.233 
50 … 50 … … Physical mix 0.745 
50 12.5 37.5 … … Physical mix 0.760 
50 25 25 … … Physical mix 0.668 
50 37.5 12.5 … … Physical mix 0.482 
50 50 … … … Granulated (polymer) 0.701 
50 … 50 … … Granulated 0.772 
50 12.5 37.5 … … Granulated 0.790 
50 25 25 … … Granulated 0.721 
50 37.5 12.5 … … Granulated 0.730 
50 50 … … … Granulated 0.719 
50 25 … 25 … Milled 0.722 
50 25 … 25 … Granules 0.310 
50 37.5 … 12.5 … Milled 0.722 
50 37.5 … 12.5 … Granules 0.336 
50 12.5 … 37.5 … Milled 0.836 
50 12.5 … 37.5 … Granules 0.429 
50 … 25 25 … Milled 0.798 
50 … 25 25 … Granules 0.118 
50 … 37.5 12.5 … Milled 0.772 
50 … 37.5 12.5 … Granules 0.224 
50 … 12.5 37.5 … Milled 0.732 
50 … 12.5 37.5 … Granules 0.131 
50 25 … … 25 Milled 0.638 
50 25 … … 25 Granules 0.345 
50 37.5 … … 12.5 Milled 0.693 
50 37.5 … … 12.5 Granules 0.397 
50 12.5 … … 37.5 Milled 0.695 
50 12.5 … … 37.5 Granules 0.387 
50 … 25 … 25 Milled 0.818 
50 … 25 … 25 Granules 0.379 
50 … 37.5 … 12.5 Milled 0.619 
50 … 37.5 … 12.5 Granules 0.472 
50 … 12.5 … 37.5 Milled 0.648 
50 … 12.5 … 37.5 Granules 0.145 
*milling was took place after granulation 
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Table 4. Melting enthalpy (J/g), peak ( ºC), % free water, and % bound water for phosphate 
buffer (control), HPMC K4M, psyllium, HPMC K4M granules, and 50 HPMC K4M + 50 Psyllium 
(mean ± SD, n=3). 
 Enthalpy (J/g)  Peak (ºC) 
% free 
water 
% bound 
water 
Phosphate buffer (pH 6.8) 260.4±22.1  5.5±2.6 100 0 
HPMC K4M 186.0±15.9  1.9±0.8 71.4±6.1 28.5±6.1 
Psyllium 197.9±4.4  2.3±0.5 76.0±1.7 24.0±1.7 
HPMC K4M granules 193.8±7.2  2.5±0.3 74.4±2.8 25.6±2.8 
50% HPMC K4M + 50% psyllium 156.5±2.7  3.1±1.2 60.1±1.0 39.9±1.0 
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Figure 1. Release rates of Theophylline from (a) tablets consist of physical mixtures of either 
Psyllium and Theophylline; (b)  Psyllium:HPMC:Theophylline (c) formulations; and release 
rates of Theophylline from granulated mixtures of Psyllium, HPMC and Theophylline tablets  
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Figure 2: Release profiles of Theophylline from granulated psyllium, EM Compress and 
Theophylline tablets (a); and release profiles of Theophylline from granulated HPMC, EM 
Compress and Theophylline tablets (b). 
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Figure 3: Release profiles of Theophylline from granulated 12.5% Psyllium, 37.5% EM 
Compress, 37.5% lactose and 50% Theophylline tablets 
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Figure 4: Release profiles of theophylline from granulated psyllium, Lactose and Theophylline 
tablets (a); and release profiles of theophylline from granulated HPMC, Lactose and 
Theophylline tablets (b). 
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Figure 5: Release profiles of Theophylline from granulated 25% Psyllium, 25% HPMC, 25% 
lactose and 50% Theophylline tablets. 
 
 
Figure 6: Comparison between 50 % Theophylline + 50 % Psyllium physical mix (ungranulated) 
and granulated tablets after the 12hr dissolution period. The tablets made from granulated 
powders maintained their integrity after the dissolution compared to the un-granulated 
formulations 
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Figure 7: SEM images of raw psyllium husk (a) and psyllium husk after being milled for 15 min 
(b). 
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Figure 8. DSC traces for pure phosphate buffer (pH=6.8), HPMC K4M, Psyllium, HPMC 
granule, and HPMC K4M granule. 
 
